Our results indicated that CSF clusterin levels were different across AD continuum influenced AD pathologies: the decreased levels of CSF clusterin at early stages are related to abnormal Aβ pathology; and the elevated levels of CSF clusterin are related to tau pathology and neurodegeneration. Here, MAPT is linked to Alzheimer disease.